FSME-Immun CC Sospensione iniettabile in una siringa Preriempita Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

fsme-immun cc sospensione iniettabile in una siringa preriempita

pfizer ag - virus fsme inactivatus (stamm neudörfl) - sospensione iniettabile in una siringa preriempita - virus fsme inactivatus (stamm neudörfl) 2.4 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.35 mg, albuminum seri humani, natrii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.42 mg et kalium 0.013 mg, residui: saccharum, formaldehydum, protamini sulfas, neomycinum, gentamicinum. - immunizzazione attiva contro l'encefalite da zecche, che abbiano compiuto il 16. anni - vaccini

FSME-Immun 0.25 ml Junior Sospensione iniettabile in una siringa Preriempita Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

fsme-immun 0.25 ml junior sospensione iniettabile in una siringa preriempita

pfizer ag - virus fsme inactivatus (stamm neudörfl) - sospensione iniettabile in una siringa preriempita - virus fsme inactivatus (stamm neudörfl) 1.19 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.17 mg, albuminum seri humani, natrii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.25 ml corresp. natrium 0.71 mg et kalium 0.007 mg, residui: saccharum, formaldehydum, protamini sulfas, neomycinum, gentamicinum. - immunizzazione attiva contro l'encefalite da zecche, di età 1. fino all'età di 16. anni - vaccini

FSME-Immun CC Sospensione per Iniezione intramuscolare Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

fsme-immun cc sospensione per iniezione intramuscolare

pfizer ag - virus fsme inactivatus (stamm neudörfl) - sospensione per iniezione intramuscolare - virus fsme inactivatus (stamm neudörfl) 2.4 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.35 mg, albuminum seri humani, natrii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.42 mg et kalium 0.013 mg, residui: saccharum, formaldehydum, protamini sulfas, neomycinum, gentamicinum. - immunizzazione attiva contro l'encefalite da zecche, che abbiano compiuto il 16. anni - vaccini

FSME-Immun 0.25 ml Junior Sospensione per Iniezione intramuscolare Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

fsme-immun 0.25 ml junior sospensione per iniezione intramuscolare

pfizer ag - virus fsme inactivatus (stamm neudörfl) - sospensione per iniezione intramuscolare - virus fsme inactivatus (stamm neudörfl) 1.19 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.17 mg, albuminum seri humani, natrii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.25 ml corresp. natrium 0.71 mg et kalium 0.007 mg, residui: saccharum, formaldehydum, protamini sulfas, neomycinum, gentamicinum. - immunizzazione attiva contro l'encefalite da zecche, di età 1. fino all'età di 16. anni - vaccini

Buccalin compresse Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

buccalin compresse

laboratorio farmaceutico s.i.t. - specialità igienico terapeutiche s.r.l., mede, succursale di chiasso - haemophilus influenzae inactivatus, streptococcus pneumoniae inactivatus (i,ii,iii), streptococcus haemolyticus inactivatus, staphylococcus aureus inactivatus - compresse - haemophilus influenzae inactivatus 1500 mio cfu, streptococcus pneumoniae inactivatus (i,ii,iii) 1000 mio cfu, streptococcus haemolyticus inactivatus 1000 mio cfu, staphylococcus aureus inactivatus 1000 mio cfu, fel bovis depuratum siccatum, lactosum monohydricum 173 mg, povidonum, magnesii stearas, coperta: lacca, e 172, talcum, pro compresso obducto. - stimolo immune in caso di raffreddori batterici - batteri e hefepräparate

Buccalin compresse Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

buccalin compresse

laboratorio farmaceutico s.i.t. - specialità igienico terapeutiche s.r.l., mede, succursale di chiasso - haemophilus influenzae inactivatus, streptococcus pneumoniae inactivatus (i,ii,iii), streptococcus haemolyticus inactivatus, staphylococcus aureus inactivatus - compresse - haemophilus influenzae inactivatus 1500 mio cfu, streptococcus pneumoniae inactivatus (i,ii,iii) 1000 mio cfu, streptococcus haemolyticus inactivatus 1000 mio cfu, staphylococcus aureus inactivatus 1000 mio cfu, fel bovis depuratum siccatum, lactosum monohydricum 173 mg, povidonum, magnesii stearas, coperta: lacca, e 172, talcum, pro compresso obducto. - stimolo immune in caso di raffreddori batterici - batteri e hefepräparate

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics European Union - Italian - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza virus antigeni di superficie (emoagglutinina e neuraminidasi) del ceppo a/vietnam/1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccini - immunizzazione attiva contro il sottotipo h5n1 del virus dell'influenza a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

CircoMax Myco European Union - Italian - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologici per suidi - suini da ingrasso) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.